50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Alnylam Pharmaceuticals EVP Tanguler sells $368,685 in stock

Published 2024-11-27, 05:24 p/m
ALNY
-

CAMBRIDGE, MA—Tanguler Tolga, Executive Vice President and Chief Commercial Officer at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transactions, which took place on November 26, 2024, involved the sale of 1,469 shares at prices ranging from $247.77 to $252.27, totaling approximately $368,685.

In addition to these sales, Tolga acquired 3,000 shares on November 25, 2024, through a performance-based stock unit vesting, as part of the company's 2018 Stock Incentive Plan. The shares were issued following the achievement of specific performance measures linked to the company's therapeutic developments.

In other recent news, Alnylam Pharmaceuticals has seen notable developments in its operations and product pipeline. The company reported a significant 34% year-over-year increase in global net product revenue, totaling $420 million, predominantly driven by its transthyretin amyloidosis treatments. The FDA is currently reviewing Alnylam's supplemental New Drug Application for vutrisiran, a potential treatment for ATTR amyloidosis with cardiomyopathy.

Furthermore, Alnylam received FDA approval for its drug Attruby, which is expected to compete with other treatments in the ATTR-CM market. Canaccord Genuity (TSX:CF) maintained a Buy rating on Alnylam's shares, anticipating a potential price adjustment for Amvuttra to align with the branded tafamidis price.

Meanwhile, BMO (TSX:BMO) Capital reiterated an Outperform rating for the company, indicating a high probability of acceptance for Amvuttra's supplemental New Drug Application without the need for an Advisory Committee meeting. However, Wolfe Research downgraded Alnylam's stock from Peer Perform to Underperform due to long-term value concerns.

Lastly, Alnylam has ceased the ALN-KHK program for type 2 diabetes but remains open to business development opportunities. These are among the recent developments at Alnylam Pharmaceuticals.

InvestingPro Insights

While Alnylam Pharmaceuticals (NASDAQ:ALNY) has seen significant insider activity, recent data from InvestingPro sheds light on the company's financial performance and market position. The company boasts a substantial market capitalization of $32.74 billion, reflecting its strong presence in the biotechnology sector.

InvestingPro data reveals that Alnylam's revenue growth stands at an impressive 21.54% over the last twelve months as of Q3 2024, indicating robust product demand and market expansion. This growth aligns with one of the InvestingPro Tips, which highlights the company's "high return over the last year." Additionally, Alnylam's gross profit margin of 85.37% underscores its efficiency in managing production costs relative to revenue.

However, investors should note that despite strong top-line growth, Alnylam is not currently profitable, with a negative operating income of $188.13 million over the same period. This observation is supported by an InvestingPro Tip stating that "analysts do not anticipate the company will be profitable this year." Nevertheless, the company's liquid assets exceed short-term obligations, suggesting a solid financial position to support ongoing operations and research initiatives.

For those seeking a deeper understanding of Alnylam's financial health and market prospects, InvestingPro offers 10 additional tips, providing valuable insights for potential investors. These tips can be crucial for evaluating the company's long-term potential in the competitive biotech landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.